1 - 25 of 38 results for author:"Bours V." in Literature citations
Results Customize
› Repeat search in UniProtKB (22)
| Overexpression of CD39 in mouse airways promotes bacteria-induced inflammation. Theatre E., Frederix K., Guilmain W., Delierneux C., Lecut C., Bettendorff L., Bours V., Oury C. J. Immunol. 189:1966-1974(2012) · Mapped (1) |
| Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. Tichomirowa M.A., Lee M., Barlier A., Daly A.F., Marinoni I., Jaffrain-Rea M.L., Naves L.A., Rodien P., Rohmer V., Faucz F.R. et al. Endocr. Relat. Cancer 19:233-241(2012) · Mapped (8) |
| High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Tichomirowa M.A., Barlier A., Daly A.F., Jaffrain-Rea M.L., Ronchi C., Yaneva M., Urban J.D., Petrossians P., Elenkova A., Tabarin A. et al. Eur. J. Endocrinol. 165:509-515(2011) · UniProtKB (1) · Mapped (3) |
| Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. Daly A.F., Tichomirowa M.A., Petrossians P., Heliovaara E., Jaffrain-Rea M.L., Barlier A., Naves L.A., Ebeling T., Karhu A., Raappana A. et al. J. Clin. Endocrinol. Metab. 95:E373-83(2010) · Mapped (4) |
| The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Stratakis C.A., Tichomirowa M.A., Boikos S., Azevedo M.F., Lodish M., Martari M., Verma S., Daly A.F., Raygada M., Keil M.F. et al. Clin. Genet. 78:457-463(2010) · Mapped (23) |
| Oligodendrocyte development and myelinogenesis are not impaired by high concentrations of phenylalanine or its metabolites. Schoemans R., Aigrot M.S., Wu C., Maree R., Hong P., Belachew S., Josse C., Lubetzki C., Bours V. J. Inherit. Metab. Dis. 33:113-120(2010) · Mapped (2) |
| The proapoptotic C16-ceramide-dependent pathway requires the death-promoting factor Btf in colon adenocarcinoma cells. Renert A.F., Leprince P., Dieu M., Renaut J., Raes M., Bours V., Chapelle J.P., Piette J., Merville M.P., Fillet M. J. Proteome Res. 8:4810-4822(2009) · Mapped (4) |
| P2X1 ion channels promote neutrophil chemotaxis through Rho kinase activation. Lecut C., Frederix K., Johnson D.M., Deroanne C., Thiry M., Faccinetto C., Maree R., Evans R.J., Volders P.G., Bours V. et al. J. Immunol. 183:2801-2809(2009) · Mapped (9) |
| Genetic analysis of Rwandan patients with cystic fibrosis-like symptoms: identification of novel cystic fibrosis transmembrane conductance regulator and epithelial sodium channel gene variants. Mutesa L., Azad A.K., Verhaeghe C., Segers K., Vanbellinghen J.F., Ngendahayo L., Rusingiza E.K., Mutwa P.R., Rulisa S., Koulischer L. et al. |
| Sensitivity of intestinal fibroblasts to TNF-related apoptosis-inducing ligand-mediated apoptosis in Crohn's disease. Reenaers C., Franchimont N., Oury C., Belaiche J., Malaise M., Bours V., Theatre E., Delvenne P., Louis E. Scand. J. Gastroenterol. 43:1334-1345(2008) · Mapped (3) |
| Neonatal screening for sickle cell disease in Central Africa: a study of 1825 newborns with a new enzyme-linked immunosorbent assay test. Mutesa L., Boemer F., Ngendahayo L., Rulisa S., Rusingiza E.K., Cwinya-Ay N., Mazina D., Kariyo P.C., Bours V., Schoos R. J Med Screen 14:113-116(2007) · Mapped (38) |
| Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. Naves L.A., Daly A.F., Vanbellinghen J.F., Casulari L.A., Spilioti C., Magalhaes A.V., Azevedo M.F., Giacomini L.A., Nascimento P.P., Nunes R.O. et al. Eur. J. Endocrinol. 157:383-391(2007) · Mapped (4) |
| An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Dideberg V., Kristjansdottir G., Milani L., Libioulle C., Sigurdsson S., Louis E., Wiman A.-C., Vermeire S., Rutgeerts P., Belaiche J. et al. Hum. Mol. Genet. 16:3008-3016(2007) · UniProtKB (1) · Mapped (11) |
| Molecular analysis in two siblings African patients with severe form of Hunter Syndrome: identification of a novel (p.Y54X) nonsense mutation. Mutesa L., Muganga N., Lissens W., Boemer F., Schoos R., Pierquin G., Bours V. J. Trop. Pediatr. 53:434-437(2007) · Mapped (6) |
| A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpoint. Lambert F., Heimann P., Herens C., Chariot A., Bours V. J Mol Diagn 9:414-419(2007) · Mapped (4) |
| Role of IKK and ERK pathways in intrinsic inflammation of cystic fibrosis airways. Verhaeghe C., Remouchamps C., Hennuy B., Vanderplasschen A., Chariot A., Tabruyn S.P., Oury C., Bours V. Biochem. Pharmacol. 73:1982-1994(2007) · Mapped (66) |
| Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. Barlier A., Vanbellinghen J.-F., Daly A.F., Silvy M., Jaffrain-Rea M.-L., Trouillas J., Tamagno G., Cazabat L., Bours V., Brue T. et al. J. Clin. Endocrinol. Metab. 92:1952-1955(2007) · UniProtKB (1) · Mapped (3) |
| Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. Daly A.F., Vanbellinghen J.-F., Khoo S.K., Jaffrain-Rea M.-L., Naves L.A., Guitelman M.A., Murat A., Emy P., Gimenez-Roqueplo A.-P., Tamburrano G. et al. J. Clin. Endocrinol. Metab. 92:1891-1896(2007) · UniProtKB (1) · Mapped (3) |
| Peroxisome proliferator-activated receptor-gamma1 is dephosphorylated and degraded during BAY 11-7085-induced synovial fibroblast apoptosis. Relic B., Benoit V., Franchimont N., Kaiser M.J., Hauzeur J.P., Gillet P., Merville M.P., Bours V., Malaise M.G. J. Biol. Chem. 281:22597-22604(2006) · Mapped (9) |
| Transcription impairment and cell migration defects in elongator-depleted cells: implication for familial dysautonomia. Close P., Hawkes N., Cornez I., Creppe C., Lambert C.A., Rogister B., Siebenlist U., Merville M.P., Slaugenhaupt S.A., Bours V. et al. |
| Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB. Benoit V., de Moraes E., Dar N.A., Taranchon E., Bours V., Hautefeuille A., Taniere P., Chariot A., Scoazec J.Y., de Moura Gallo C.V. et al. Oncogene 25:5708-5718(2006) · Mapped (38) |
| Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study. Dideberg V., Louis E., Farnir F., Bertoli S., Vermeire S., Rutgeerts P., De Vos M., Van Gossum A., Belaiche J., Bours V. Pharmacogenet. Genomics 16:369-373(2006) · Mapped (16) |
| TNFalpha- and IKKbeta-mediated TANK/I-TRAF phosphorylation: implications for interaction with NEMO/IKKgamma and NF-kappaB activation. Bonif M., Meuwis M.A., Close P., Benoit V., Heyninck K., Chapelle J.P., Bours V., Merville M.P., Piette J., Beyaert R. et al. Biochem. J. 394:593-603(2006) · Mapped (5) |
| Interleukin-6 receptor shedding is enhanced by interleukin-1beta and tumor necrosis factor alpha and is partially mediated by tumor necrosis factor alpha-converting enzyme in osteoblast-like cells. Franchimont N., Lambert C., Huynen P., Ribbens C., Relic B., Chariot A., Bours V., Piette J., Merville M.P., Malaise M. Arthritis Rheum. 52:84-93(2005) · Mapped (11) |
| GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. Viatour P., Dejardin E., Warnier M., Lair F., Claudio E., Bureau F., Marine J.C., Merville M.P., Maurer U., Green D. et al. Mol. Cell 16:35-45(2004) · UniProtKB (1) |